Exelixis Inc. (NASDAQ:EXEL) and Concert Pharmaceuticals Inc. (NASDAQ:CNCE) compete with each other in the Biotechnology sector. We will analyze and compare their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis Inc.	745.30M	9.46	368.47M	1.18	18.13
Concert Pharmaceuticals Inc.	10.50M	30.34	41.25M	-1.77	0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Exelixis Inc. and Concert Pharmaceuticals Inc.

Profitability

Table 2 has Exelixis Inc. and Concert Pharmaceuticals Inc.’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
Exelixis Inc.	49.44%	55.7%	43.8%
Concert Pharmaceuticals Inc.	-392.86%	-20.8%	-19%

Volatility & Risk

Exelixis Inc. has a 2.3 beta, while its volatility is 130.00%, thus making it more volatile than S&P 500. Concert Pharmaceuticals Inc. has a 0.94 beta and it is 6.00% less volatile than S&P 500.

Liquidity

Exelixis Inc.’s Current Ratio and Quick Ratio are 8.7 and 8.5 respectively. The Current Ratio and Quick Ratio of its competitor Concert Pharmaceuticals Inc. are 26.7 and 26.7 respectively. Concert Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Exelixis Inc.

Analyst Recommendations

The Ratings and Recommendations for Exelixis Inc. and Concert Pharmaceuticals Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Exelixis Inc.	1	1	0	2.50
Concert Pharmaceuticals Inc.	0	1	0	2.00

Exelixis Inc. has an average price target of $20.5, and a -13.10% downside potential.

Insider and Institutional Ownership

Roughly 79.2% of Exelixis Inc. shares are owned by institutional investors while 75% of Concert Pharmaceuticals Inc. are owned by institutional investors. 0.9% are Exelixis Inc.’s share owned by insiders. Insiders Competitively, owned 4.4% of Concert Pharmaceuticals Inc. shares.

Performance

Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Exelixis Inc.	5.17%	23.4%	13.62%	11.66%	-20.59%	-29.74%
Concert Pharmaceuticals Inc.	-12%	-20.34%	-12.19%	-34.53%	-49.28%	-51.26%

For the past year Exelixis Inc. has stronger performance than Concert Pharmaceuticals Inc.

Summary

Exelixis Inc. beats on 10 of the 12 factors Concert Pharmaceuticals Inc.

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The companyÂ’s products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. The companyÂ’s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with AlzheimerÂ’s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis. It product candidates that have completed Phase 1 clinical trials comprise CTP-730 for use in the treatment of inflammation or cancer; JZP-386 for use in the treatment of excessive daytime sleepiness and cataplexy; and CTP-543 for use in the treatment of alopecia areata. The company has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.